Cargando…

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry

Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tilch, Marie-Kristin, Visco, Carlo, Kinda, Sandra, Hermine, Olivier, Kohn, Milena, Besson, Caroline, Lamure, Sylvain, Duléry, Rémy, Ragaini, Simone, Eyre, Toby A., Van Meerten, Tom, Ohler, Anke, Eckerle, Steffen, Dreyling, Martin, Hess, Georg, Giné, Eva, Gomes da Silva, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000040/ https://www.ncbi.nlm.nih.gov/pubmed/35425889 http://dx.doi.org/10.1097/HS9.0000000000000711

Ejemplares similares

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
por: Morello, Lucia, et al.
Publicado: (2019)

Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
por: Drandi, Daniela, et al.
Publicado: (2020)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network
por: Klapper, Wolfram, et al.
Publicado: (2009)

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
por: Shanbhag, Satish, et al.
Publicado: (2010)

Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
por: Lamure, Sylvain, et al.
Publicado: (2020)

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
por: Eskelund, Christian Winther, et al.
Publicado: (2020)

Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma
por: Ramsower, Colleen A., et al.
Publicado: (2020)

The role of B cell antigen receptors in mantle cell lymphoma
por: Fichtner, Michael, et al.
Publicado: (2017)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma
por: Linton, Kim, et al.
Publicado: (2020)

P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.
por: Alessandria, B., et al.
Publicado: (2022)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
por: Novak, Urban, et al.
Publicado: (2023)

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
por: Serna, Angel, et al.
Publicado: (2022)

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
por: Ferrero, Simone, et al.
Publicado: (2023)

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
por: Eyre, T. A., et al.
Publicado: (2022)

Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year
por: Herrero-Vicent, Carmen, et al.
Publicado: (2016)

Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
por: Hueso, Thomas, et al.
Publicado: (2022)

Mantle cell lymphoma patients in first relapse: we pretty much know what to do
por: Quaglia, Francesca Maria, et al.
Publicado: (2021)

S221: LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)
por: Ladetto, Marco, et al.
Publicado: (2023)

Erratum: Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year
por: Herrero-Vicent, Carmen, et al.
Publicado: (2016)

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma
por: Ferrero, Simone, et al.
Publicado: (2022)

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins
por: Li, Yijing, et al.
Publicado: (2023)

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
por: Freile, Jimena Álvarez, et al.
Publicado: (2022)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
por: Wang, Michael, et al.
Publicado: (2017)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL)
por: Lisson, Catharina Silvia, et al.
Publicado: (2022)

A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
por: Ghaderi, Amineh, et al.
Publicado: (2022)

Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada
por: Anglin, Peter, et al.
Publicado: (2023)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
por: Alsuliman, Tamim, et al.
Publicado: (2021)

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
por: Sancho, Juan-Manuel, et al.
Publicado: (2022)

Mantle flow distribution beneath the California margin
por: Barbot, Sylvain
Publicado: (2020)

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
por: Scheubeck, Gabriel, et al.
Publicado: (2023)

Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80—results from a single-center survey
por: Freudenberger, Felix, et al.
Publicado: (2021)

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
por: Rule, Simon A., et al.
Publicado: (2019)

Maintenance Treatment for Patients With Mantle Cell Lymphoma: A Systematic Review and Meta-analysis of Randomized Trials
por: Vidal, Liat, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3ngacplk801h2ctpk54lnvfd4h